Acura Pharmaceuticals, Inc. (Nasdaq:ACUR)
September 22nd, 2018
Acura Pharmaceuticals, Inc. finished Friday’s trading session down 16.69%, a $0.03 decrease to close on $0.13. Acura Pharmaceuticals, Inc. bounced 23.08% between high and low. In addition to the stock finishing lower, the trading volumes were only 10% of normal which could be an indication of investor uncertainty.
ACUR was outperformed by the rest of the Healthcare sector which went up 0.19%.
The market sectors were mixed Saturday with a majority of the sectors trending up. Telecommunication Services saw the biggest increase of the day (0.98%), while Financials saw the biggest drop (0.36%). Consumer Discretionary has seen the biggest year-to-date gain at 19%. The biggest loss this year has been the Telecommunication Services sector dropping 4.34%.
Utilities saw the biggest turnaround from its 5-day performance of -1.53%, as it went up 0.39%. Financials and Consumer Discretionary saw turn arounds from their five day positive performance, Financials with a drop of 0.36%.
- Telecommunication Services went up with a 0.98% change.
- Energy went up with a 0.72% change.
- Utilities went up with a 0.39% change.
- Industrials went up with a 0.31% change.
- Consumer Staples went up with a 0.26% change.
- Healthcare went up with a 0.19% change.
- Real Estate went down with a -0.13% change.
- Materials went down with a -0.23% change.
- Consumer Discretionary went down with a -0.28% change.
- Information Technology went down with a -0.34% change.
- Financials went down with a -0.36% change.
Acura Pharmaceuticals, Inc. Info
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.